2019
DOI: 10.1111/jns.12302
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

Abstract: Intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). To investigate the efficacy and safety of the IVIG IgPro10 (Privigen) for treatment of CIDP, results from Privigen Impact on Mobility and Autonomy (PRIMA), a prospective, open‐label, single‐arm study of IVIG in immunoglobulin (Ig)‐naïve or IVIG pre‐treated subjects (NCT01184846, n = 28) and Polyneuropathy And Treatment with Hizentra (PATH), a double‐blind, randomized study including an open‐la… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
14
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 23 publications
(17 citation statements)
references
References 18 publications
3
14
0
Order By: Relevance
“…Our percentage of patients with TAEs is at the lower end of adverse event rates, as reported in a Cochrane systematic review of IVIG TAEs, which ranged between 0.6% and 71% 11 . However, the frequency of TAEs for infusion rates in this study are similar to other cohorts 12,13 …”
Section: Discussionsupporting
confidence: 72%
“…Our percentage of patients with TAEs is at the lower end of adverse event rates, as reported in a Cochrane systematic review of IVIG TAEs, which ranged between 0.6% and 71% 11 . However, the frequency of TAEs for infusion rates in this study are similar to other cohorts 12,13 …”
Section: Discussionsupporting
confidence: 72%
“…Immunotherapies that have been shown to be effective in the treatment of CIDP include glucocorticoids, intravenous immunoglobulin (IVIG), subcutaneous immunoglobulin, and plasma exchange . Intravenous immunoglobulin is the first‐line treatment in most patients . Steroids, administered in pulsed or daily doses, are also used as first‐line treatment, but their associated adverse effects make long‐term treatment difficult .…”
Section: Introductionmentioning
confidence: 99%
“…In addition, no new safety finding or trend arised from this study confirming the known safety profile of this group of therapies. 15…”
Section: Discussionmentioning
confidence: 99%